Approximately 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors need to be replaced due to a risk of incorrect glucose readings. Abbott has received reports of 736 severe adverse events and seven deaths that may be related to this issue.
The timing of this new guidance from the Heart Rhythm Society and American College of Cardiology could not have been better—the document went live just as CMS finalized its decision to cover cardiac ablation procedures performed in ASCs.
Gregg Stone, MD, spoke to Cardiovascular Business about early data from the ATHENS-HF trial. Ten heart failure patients were treated with the adjustable device, and each implant was a success.
The largest healthcare system in the Middle East is partnering with Nvidia to decode the human genome. If successful, the AI-heavy project will translate almost the entire language of heredity into actionable information.
There have been reports of the retrievable device being difficult to use in a way that increases the risk of patients injuries. Customers are urged to stop using these devices right away.
Advanced Imaging Specialists, Danbury, Connecticut, alleges the breach of contract occurred shortly after it started performing services for 3 New England hospitals.
U.S. Reps. Kathy Castor, D-Fla., Brian Fitzpatrick, R-Pa., and Debbie Wasserman Schultz, D-Fla., recently reintroduced the Increasing Access to Lung Cancer Screening Act.
Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?
According to Hexoskin, the newly cleared technology offers significant value for hospitals and health systems as well as researchers conducting clinical trials.
Filed in a Texas federal court, the complaint names Prime Imaging Partners and Memorial MRI & Diagnostic among numerous defendants, with the alleged auto-injury scheme occurring from 2019-2023.
Approximately 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors need to be replaced due to a risk of incorrect glucose readings. Abbott has received reports of 736 severe adverse events and seven deaths that may be related to this issue.
The timing of this new guidance from the Heart Rhythm Society and American College of Cardiology could not have been better—the document went live just as CMS finalized its decision to cover cardiac ablation procedures performed in ASCs.
Gregg Stone, MD, spoke to Cardiovascular Business about early data from the ATHENS-HF trial. Ten heart failure patients were treated with the adjustable device, and each implant was a success.
